Pages that link to "Q28211902"

The following pages link to Unstable angina, stroke, myocardial infarction and death in aspirin non-responders. A prospective, randomized trial. The ASCET (ASpirin non-responsiveness and Clopidogrel Endpoint Trial) design (Q28211902):

Displaying 22 items.

• Thienopyridine derivatives versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients (Q24240326) (← links)
• (Q28173824) (redirect page) (← links)
• Antiplatelet resistance with aspirin and clopidogrel: is it real and does it matter? (Q28199136) (← links)
• Gender differences of polymorphisms in the TF and TFPI genes, as related to phenotypes in patients with coronary heart disease and type-2 diabetes. (Q33900427) (← links)
• The MMP-9 -1562 C/T polymorphism in the presence of metabolic syndrome increases the risk of clinical events in patients with coronary artery disease (Q34142412) (← links)
• The co-existence of the IL-18 183 A/G and MMP-9 -1562 C/T polymorphisms is associated with clinical events in coronary artery disease patients (Q34990054) (← links)
• Circulating levels of IL-18 are significantly influenced by the IL-18 183 A/G polymorphism in coronary artery disease patients with diabetes type 2 and the metabolic syndrome: an observational study (Q35808941) (← links)
• High On-Aspirin Platelet Reactivity and Clinical Outcome in Patients With Stable Coronary Artery Disease: Results From ASCET (Aspirin Nonresponsiveness and Clopidogrel Endpoint Trial) (Q36366209) (← links)
• Implementation of standardized assessment and reporting of myocardial infarction in contemporary randomized controlled trials: a systematic review (Q36705836) (← links)
• Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Wo (Q37378896) (← links)
• Mouse embryonic stem cells undergo charontosis, a novel programmed cell death pathway dependent upon cathepsins, p53, and EndoG, in response to etoposide treatment (Q37584840) (← links)
• Variable platelet responsiveness to aspirin and clopidogrel: role of platelet function and genetic polymorphism testing (Q37636719) (← links)
• Thrombocardiology: an update (Q37707396) (← links)
• A contemporary viewpoint on 'aspirin resistance'. (Q37989558) (← links)
• Antiplatelet therapy: aspirin resistance and all that jazz! (Q38023196) (← links)
• Advances in monitoring of aspirin therapy. (Q38032895) (← links)
• Overcoming aspirin treatment failure in diabetes. (Q38055245) (← links)
• The influence of CYP 2C19*2 polymorphism on platelet function testing during single antiplatelet treatment with clopidogrel (Q42159559) (← links)
• Is aspirin resistance valid? (Q43267017) (← links)
• Assessment of platelet function by whole blood impedance aggregometry in coronary artery bypass grafting patients on acetylsalicylic acid treatment may prompt a switch to dual antiplatelet therapy (Q44196402) (← links)
• Aspirin resistance: myth or major problem? (Q46494010) (← links)
• vWF/ADAMTS13 is associated with on-aspirin residual platelet reactivity and clinical outcome in patients with stable coronary artery disease. (Q47098383) (← links)